Executive Insider Buying Signals Confidence in BioCardia, Inc. (NASDAQ: BCDA) Amidst Regulatory Review and Q1 2026 Financials

Font: Financial Modeling Prep  • May 15, 2026

• A key executive at BioCardia, Inc. made a significant stock purchase, increasing his direct ownership.
• The company is actively engaging with Japan's PMDA regarding its CardiAMP cell therapy, BCDA-01, for regulatory approval.
• BioCardia reported its Q1 2026 financial results, with its stock experiencing a daily decrease despite the insider activity.

BioCardia, Inc. (NASDAQ: BCDA) is a company that develops treatments for heart and lung diseases. On May 15, 2026, a key executive made a notable stock purchase. This comes as the company navigates regulatory processes for its main product and reports its quarterly financial performance to investors.

Altman Peter, who is a director, President, and CEO of BioCardia, bought 5,100 shares of the company's common stock. The transaction occurred at a price of $1.02 per share. This purchase increases his direct ownership in the company to a total of 285,866 shares.

This insider activity coincides with the release of the company's first-quarter 2026 financial results, as highlighted by GlobeNewswire. The stock is currently trading at $1.01 per share, which is a decrease of 7.34% for the day. The share price has moved between a low of $1.01 and a high of $1.10.

As part of its business update, BioCardia is addressing questions from Japan's Pharmaceuticals and Medical Devices Agency (PMDA). The questions concern the safety and effectiveness of its CardiAMP cell therapy, BCDA-01. The company has scheduled a conference call to discuss these developments and its financial results.

Over the past year, BioCardia shares have traded as high as $2.49 and as low as $1.00. The company currently has a market capitalization of approximately $5.86 million. Market capitalization is the total value of all a company's shares of stock. The trading volume for the day is 311,620 shares.